Tumor necrosis factor α (TNF-α) plays a central role in the pathophysiology of Alzheimer’s disease (AD). Food and Drug Administration–approved biologic TNF-α inhibitors are thus a potential treatment for AD, but they do not cross the blood-brain barrier. In this short review, we discuss the involvement of TNF-α in AD, challenges associated with the development of existing biologic TNF-α inhibitors for AD, and potential therapeutic strategies for targeting TNF-α for AD therapy.
Chang R, Yee KL, Sumbria RK. Tumor necrosis factor α Inhibition for Alzheimer's Disease. J Cent Nerv Syst Dis. 2017;9:1179573517709278. https://doi.org/10.1177/1179573517709278
Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial 4.0 License
Animal Experimentation and Research Commons, Medical Neurobiology Commons, Nervous System Diseases Commons, Other Chemicals and Drugs Commons, Other Pharmacy and Pharmaceutical Sciences Commons, Pharmaceutical Preparations Commons, Therapeutics Commons